← Back to patent-cliff list
Dexamethasone/Netilmicin Sulfate
Tier C — Watch / tradeDexamethasone/Netilmicin Sulfate
Usa
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GR, 30S subunit
Brand：Netildex
Indications (approved)：Multiple myeloma, 白内障
Regional status
US
Phase II
2018-04-26
EU
Phase II
2018-04-26
China
-
Japan
Phase II
2018-04-26
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Dexamethasone/Netilmicin Sulfate?
Approved indications include: Multiple myeloma, 白内障.
When does the Dexamethasone/Netilmicin Sulfate patent expire?
No public expiry year is available for Dexamethasone/Netilmicin Sulfate yet; this page updates once verified.
How do I get a quote for Dexamethasone/Netilmicin Sulfate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08